Intec Parent Inc
NASDAQ:NTEC (8/3/2021, 7:09:11 PM)
After market: 9.9 +0.27 (+2.8%)9.63
-1.37 (-12.48%)
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. The company is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The firm is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.
Intec Parent Inc
12 Hartom Street, Har Hotzvim
JERUSALEM 777512
P: 97225864657.0
CEO: Jeffrey A. Meckler
Employees: 70
Website: https://www.intecpharma.com
Completes $30 Million Private Placement
NTEC stock is riding high today without any news. It seems investors are getting hyped up ahead of its merger with Decoy Biosystems.
These Former Penny Stocks Are Turning Heads Ahead Of Robinhood IPO
Here you can normally see the latest stock twits on NTEC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: